Cocrystal Pharma, Inc

(NASDAQ:COCP)

Latest On Cocrystal Pharma, Inc (COCP):

Date/Time Type Description Signal Details
2023-05-31 18:34 ESTNewsCocrystal cleared to run Phase 1 trial for COVID-19 drug in AustraliaN/A
2023-05-15 22:25 ESTNewsCocrystal Pharma GAAP EPS of -$0.64 misses by $0.05N/A
2023-04-10 20:48 ESTNewsCocrystal Pharma completes $4M equity offering priced ATMN/A
2023-03-29 10:52 ESTNewsCocrystal Pharma GAAP EPS of -$4.77N/A
2022-11-15 00:23 ESTNewsCocrystal Pharma GAAP EPS of -$0.70 misses by $0.21N/A
2022-10-24 20:18 ESTNewsCocrystal Pharma (COCP) Presents At Dawson James Securities 2022 Small Cap Growth Conference - SlideshowN/A
2022-10-11 14:02 ESTNewsCocrystal selects its antiviral drug candidate to develop as a treatment for COVID-19N/A
2022-08-15 13:11 ESTNewsCocrystal Pharma GAAP EPS of -$0.25 misses by $0.21N/A
2022-08-09 00:34 ESTNewsCocrystal engages Open Orphan to conduct mid-stage trial of oral influenza drug in UKN/A
2022-07-14 20:34 ESTNewsCocrystal Pharma completes single ascending dose of phase 1 study of influenza A drugN/A
2022-05-11 21:27 ESTNewsCocrystal Pharma GAAP EPS of -$0.04 in-lineN/A
2022-04-21 16:55 ESTNewsCocrystal, NIAID ink pact to explore COVID-19 protease inhibitors in preclinical studiesN/A
2022-04-12 10:04 ESTNewsCocrystal Pharma oral antiviral CC-42344 for influenza A shows safety in interim phase 1 dataN/A
2022-03-24 07:38 ESTNewsCocrystal Pharma GAAP EPS of -$0.16 in-lineN/A
2022-03-10 14:10 ESTNewsCocrystal Pharma begins dosing of antiviral CC-42344 in phase 1 influenza A trialN/A
2022-01-27 12:40 ESTNewsCocrystal Pharma picks two oral antiviral candidates for COVID-19N/A
2021-12-22 14:42 ESTNewsCocrystal highlights antiviral effect of its protease inhibitors against OmicronN/A
2021-11-02 14:10 ESTNewsWarning: COCP is at high risk of performing badlyN/A
2021-11-01 17:21 ESTNewsCocrystal Pharma submits pre-IND package to FDA for COVID-19 candidateN/A
2021-10-07 07:26 ESTNewsCocrystal Pharma receives Australian clearance to initiate Phase 1 study of CC-42344N/A
2021-09-21 14:50 ESTNewsCocrystal Pharma (COCP) Investor Presentation - SlideshowN/A
2021-08-16 15:43 ESTNewsCocrystal Pharma EPS in-lineN/A
2021-07-29 16:18 ESTNewsCocrystal's stock jumps 25% after CDI-45205 shows encouraging antiviral activity against Delta, Gamma variantsN/A
2021-07-21 01:50 ESTNewsCocrystal’s soars 11% as CDI-45205 shows excellent antiviral activity against SARS-CoV-2 and variantsN/A
2021-07-21 01:39 ESTNewsCocrystal Pharma plans to initiate a phase 1 trial of CC-42344 in Q3 2021N/A
2021-07-21 01:35 ESTNewsCocrystal Pharma added to Russell Microcap IndexN/A
2021-05-05 13:54 ESTNewsCocrystal Pharma launches $40M stock offeringN/A
2021-05-03 20:15 ESTNewsCocrystal Pharma updates on COVID-19 antiviral development programsN/A
2021-03-19 04:41 ESTFinancialsCompany financials have been released.Neutral
2021-03-18 12:25 ESTEarnings EstimateAn EPS average of -$0.04 is estimated for the quarter ending on June 30, 2021.Sell
2021-03-17 20:47 ESTNewsCocrystal Pharma EPS beats by $0.03, misses on revenueN/A
2021-01-21 07:30 ESTNewsCocrystal Pharma (COCP) Investor Presentation -SlideshowN/A
2021-01-19 11:00 ESTNewsCocrystal Pharma further develops influenza A/B antiviral compounds under collaboration with MerckN/A
2021-01-11 16:09 ESTNewsCocrystal sees 2021 cash burn of $800k a monthN/A
2020-12-22 18:03 ESTNewsCocrystal Pharma to test CDI-45205 against coronavirusesN/A
2020-12-13 03:38 ESTFinancialsCompany financials have been released.Neutral
2020-12-06 17:03 ESTFinancialsCompany financials have been released.Neutral
2020-11-24 07:34 ESTFinancialsCompany financials have been released.Neutral
2020-11-18 11:31 ESTAnalyst RatingThe Analyst Target Price has increased from $4.5 to $4.75.Buy
2020-11-17 19:28 ESTFinancialsCompany financials have been released.Neutral
2020-11-17 05:14 ESTNewsCocrystal Pharma misses on revenueN/A
2020-11-17 03:35 ESTEarnings EstimateAn EPS average of -$0.04 is estimated for the quarter ending on March 31, 2021.Buy
2020-11-13 11:38 ESTAnalyst RatingThe Analyst Target Price has decreased from $4.67 to $4.5.Neutral
2020-11-07 15:27 ESTFinancialsCompany financials have been released.Neutral
2020-11-01 17:35 ESTFinancialsCompany financials have been released.Neutral
2020-09-19 08:40 ESTFinancialsCompany financials have been released.Neutral
2020-09-17 04:31 ESTFinancialsCompany financials have been released.Neutral
2020-08-27 16:00 ESTNewsCocrystal trades in red; announces $10M bought deal offeringN/A
2020-08-27 15:59 ESTNewsCocrystal Pharma raises "bought deal" offering to $15MN/A
2020-08-08 16:27 ESTFinancialsCompany financials have been released.Neutral

About Cocrystal Pharma, Inc (COCP):

Cocrystal Pharma, Inc., a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, and norovirus infections. The company develops CC-31244, a HCV non-nucleoside polymerase inhibitor that is in Phase 2a clinical trial to treat HCV infection; and CC-42344, a PB2 inhibitor that is in preclinical development trials for treating influenza infection. It is also involved in identifying and developing non-nucleoside polymerase inhibitors for norovirus infections. Cocrystal Pharma, Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. to discover and develop proprietary influenza A/B antiviral agents; a license agreement with Kansas State University Research Foundation to develop antiviral compounds for the treatment of norovirus and coronavirus infections; and drug discovery collaboration with HitGen and InterX, Inc. The company is headquartered in Bothell, Washington.

COCP Quotes by TradingView

See Advanced Chart

General

  • Name Cocrystal Pharma, Inc
  • Symbol COCP
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 11
  • Last Split Factor1:30
  • Last Split Date2018-01-24
  • Fiscal Year EndDecember
  • IPO Date2011-05-19
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryPharmaceuticals
  • Gic SubIndustryPharmaceuticals
  • Web URLhttp://www.cocrystalpharma.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 39.86
  • Price/Book (Most Recent Quarter) 2.34
  • Enterprise Value Revenue 42.74
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.17
  • Next Quarter EPS Estimate -$0.04
  • Operating Margin -476%
  • Return on Assets -14%
  • Return on Equity -25%
  • Revenue 2.01 million
  • Earnings Per Share -$1.47
  • Revenue Per Share $0.04
  • Gross Profit 2.01 million
  • Quarterly Earnings Growth 26.9%
View More

Highlights

  • Market Capitalization 107.92 million
  • EBITDA -3424000
  • Analyst Target Price $4.75
  • Book Value Per Share $0.75
View More

Share Statistics

  • Shares Outstanding 71.47 million
  • Shares Float 47.6 million
  • % Held by Insiders 2904%
  • % Held by Institutions 23.76%
  • Shares Short 2.21 million
  • Shares Short Prior Month 2.21 million
  • Short Ratio 0.79
  • Short % of Float 4%
  • Short % of Shares Outstanding 3%
View More

Technicals

  • Beta 0.91
  • 52 Week High $2.48
  • 52 Week Low $0.6
  • 50 Day Moving Average 1.76
  • 200 Day Moving Average 1.34
View More

Dividends

  • Dividend Date 2018-01-24
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Cocrystal Pharma, Inc (COCP) Dividend Calendar:

COCP's last dividend payment was made to shareholders on January 24, 2018.

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Cocrystal Pharma, Inc (COCP) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312020-12-31$510000-$0.01-$0.0475%
2020-09-302020-11-13$N/A-$0.05-$0.055.8%
2020-06-302020-08-06$N/A-$0.07-$0.04-65.5%
2020-03-312020-05-13$461000-$0.05-$0.0837.5%
2019-12-312020-03-27$402000-$0.07-$0.076.57%
2019-09-302019-11-12$492000-$0.07-$0.088.88%
2019-06-302019-08-09$592000-$0.07-$0.073%
2019-03-312019-05-10$5.08 million$0.10-$0.08225%
2018-12-312018-12-31$N/A$0.34-$0.08525%
2018-09-302018-11-09$N/A-$0.06-$0.0825%
2018-06-302018-08-09$N/A-$0.05-$0.0728.57%
2018-03-312018-05-10$N/A-$0.06
2017-12-312018-03-21$N/A$0.20
2017-09-302017-09-30$N/A-$0.09
2017-06-302017-06-30$N/A-$0.04
2017-03-312017-03-31$N/A-$0.11
2016-12-312016-12-31$N/A-$2.76
2016-09-302016-09-30$N/A-$0.08
2016-06-302016-06-30$N/A-$0.14
2016-03-312016-03-31$N/A-$0.17
2015-12-312015-12-31$53000-$1.32
2015-09-302015-09-30$25000-$0.02
2015-06-302015-06-30$27000-$0.11
2015-03-312015-03-31$26000-$1.13
2014-12-312014-12-31$9000-$0.46
2014-09-302014-09-30$N/A-$0.16
2014-06-302014-06-30$N/A-$0.08
2014-03-312014-03-31$N/A-$0.03
2013-09-302013-09-30-$1.98
2013-06-302013-06-30-$0.33
2013-03-312013-03-31-$0.70

Cocrystal Pharma, Inc (COCP) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares
Cash Flow:
Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures
Balance Sheet:
Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

Cocrystal Pharma, Inc (COCP) Chart:

Cocrystal Pharma, Inc (COCP) News:

Below you will find a list of latest news for Cocrystal Pharma, Inc (COCP) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Cocrystal Pharma, Inc (COCP) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent

Latest COCP Trades:

Date Shares Price
Jun 13, 2022 6:38 PM EST100$0.3879
Jun 13, 2022 6:39 PM EST100$0.3879
Jun 13, 2022 2:05 PM EST500$0.38

Cocrystal Pharma, Inc (COCP) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-07-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1412486/000149315220012439/0001493152-20-012439-index.htm
2020-04-27UPLOADSEC-generated letterhttps://www.sec.gov/Archives/edgar/data/1412486/000000000020003571/0000000000-20-003571-index.htm
2020-02-10SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1412486/000081413320000040/0000814133-20-000040-index.htm
2020-03-03SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1412486/000081413320000047/0000814133-20-000047-index.htm
2019-11-22SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1412486/000094480919000082/0000944809-19-000082-index.htm
2020-03-10SC 13D/AGeneral statement of acquisition of beneficial ownershiphttps://www.sec.gov/Archives/edgar/data/1412486/000094480920000009/0000944809-20-000009-index.htm
2020-03-06SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1412486/000110465920029961/0001104659-20-029961-index.htm
2020-02-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1412486/000119312520029852/0001193125-20-029852-index.htm
2020-02-28SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1412486/000119312520056539/0001193125-20-056539-index.htm
2019-10-30424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1412486/000149315219016209/0001493152-19-016209-index.htm
2019-10-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1412486/000149315219016212/0001493152-19-016212-index.htm
2019-10-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1412486/000149315219016250/0001493152-19-016250-index.htm
2019-10-31424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1412486/000149315219016270/0001493152-19-016270-index.htm
2019-10-31424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1412486/000149315219016273/0001493152-19-016273-index.htm
2019-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1412486/000149315219016555/0001493152-19-016555-index.htm
2019-11-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1412486/000149315219016837/0001493152-19-016837-index.htm
2019-12-168-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1412486/000149315219019230/0001493152-19-019230-index.htm
2020-01-298-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1412486/000149315220001295/0001493152-20-001295-index.htm
2020-01-31424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1412486/000149315220001411/0001493152-20-001411-index.htm
2020-01-318-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1412486/000149315220001412/0001493152-20-001412-index.htm
2020-01-31424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1412486/000149315220001413/0001493152-20-001413-index.htm
2020-02-188-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1412486/000149315220002638/0001493152-20-002638-index.htm
2020-02-248-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1412486/000149315220002874/0001493152-20-002874-index.htm
2020-02-28424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1412486/000149315220003124/0001493152-20-003124-index.htm
2020-03-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1412486/000149315220003315/0001493152-20-003315-index.htm
2020-03-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1412486/000149315220003365/0001493152-20-003365-index.htm
2020-03-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1412486/000149315220003572/0001493152-20-003572-index.htm
2020-03-10424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1412486/000149315220003659/0001493152-20-003659-index.htm
2020-03-138-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1412486/000149315220003917/0001493152-20-003917-index.htm
2020-03-2710-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1412486/000149315220004916/0001493152-20-004916-index.htm
2020-03-308-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1412486/000149315220004992/0001493152-20-004992-index.htm
2020-04-17S-3Registration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1412486/000149315220006643/0001493152-20-006643-index.htm
2020-04-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1412486/000149315220006703/0001493152-20-006703-index.htm
2020-04-228-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1412486/000149315220006885/0001493152-20-006885-index.htm
2020-04-273Initial statement of beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1412486/000149315220007143/0001493152-20-007143-index.htm
2020-04-28DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1412486/000149315220007265/0001493152-20-007265-index.htm
2020-04-28DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1412486/000149315220007278/0001493152-20-007278-index.htm
2020-05-04S-3/ARegistration statement under Securities Act of 1933https://www.sec.gov/Archives/edgar/data/1412486/000149315220007657/0001493152-20-007657-index.htm
2020-05-04CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1412486/000149315220007658/0001493152-20-007658-index.htm
2020-05-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1412486/000149315220008160/0001493152-20-008160-index.htm
2020-05-11CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1412486/000149315220008291/0001493152-20-008291-index.htm
2020-05-12CORRESPCorrespondencehttps://www.sec.gov/Archives/edgar/data/1412486/000149315220008313/0001493152-20-008313-index.htm
2020-05-1310-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1412486/000149315220008508/0001493152-20-008508-index.htm
2020-06-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1412486/000149315220010746/0001493152-20-010746-index.htm
2020-06-158-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1412486/000149315220011180/0001493152-20-011180-index.htm
2020-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1412486/000149315220011715/0001493152-20-011715-index.htm
2020-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1412486/000149315220011716/0001493152-20-011716-index.htm
2020-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1412486/000149315220011718/0001493152-20-011718-index.htm
2020-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1412486/000149315220011730/0001493152-20-011730-index.htm
2020-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1412486/000149315220011748/0001493152-20-011748-index.htm
2020-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1412486/000149315220011751/0001493152-20-011751-index.htm
2020-06-244Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1412486/000149315220011752/0001493152-20-011752-index.htm
2020-06-268-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1412486/000149315220011937/0001493152-20-011937-index.htm
2020-07-01424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1412486/000149315220012398/0001493152-20-012398-index.htm
2020-07-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1412486/000149315220012439/0001493152-20-012439-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1412486/000149315220014811/0001493152-20-014811-index.htm
2020-08-26424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1412486/000149315220016778/0001493152-20-016778-index.htm
2020-08-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1412486/000149315220016784/0001493152-20-016784-index.htm
2020-08-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1412486/000149315220016799/0001493152-20-016799-index.htm
2020-08-27424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1412486/000149315220016850/0001493152-20-016850-index.htm
2020-08-278-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1412486/000149315220016851/0001493152-20-016851-index.htm
2020-10-028-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1412486/000149315220018769/0001493152-20-018769-index.htm
2020-11-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1412486/000149315220020718/0001493152-20-020718-index.htm
2020-02-27SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1412486/000153561020000076/0001535610-20-000076-index.htm
2020-05-13EFFECTNotice of Effectivenesshttps://www.sec.gov/Archives/edgar/data/1412486/999999999520001143/9999999995-20-001143-index.htm